MGAT4A and neoplasm: In this study, we successfully identified that glycosyltransferase MGAT4A was a potential biomarker for distinguishing poor prognostic EC subtype and characterized its tumor promoting role in EC development via reprogramming glucose metabolism, as evidenced below: 1) An unsupervised clustering analysis identified an 11‐glycogene cluster, which was characterized with poor prognosis and enriched with TP53 mutation, using the public EC dataset TCGA‐UCEC (n = 543).